Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-ABVD vs ABVD-RT in Limited Stage Hodgkin's Lymphoma
NCT00992030Phase 3Terminated
- Sponsor
- Michelangelo Foundation
- Start
- Sep 2009
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of rituximab in Hodgkin lymphoma (HL), sponsored by Michelangelo Foundation. Started Sep 2009; status: terminated.
02
Drugs
rituximab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00992030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00992030.